Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Recommendation of “Buy” by Brokerages

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) have been assigned a consensus rating of “Buy” from the ten brokerages that are presently covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $11.50.

Several research firms have issued reports on CATX. UBS Group reiterated a “buy” rating and issued a $7.00 target price (down previously from $18.00) on shares of Perspective Therapeutics in a research note on Friday, November 21st. BTIG Research began coverage on shares of Perspective Therapeutics in a research report on Friday, October 10th. They issued a “buy” rating and a $14.00 price objective on the stock. Wedbush reiterated an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, November 11th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Perspective Therapeutics in a research note on Friday, October 3rd. Finally, B. Riley cut their price target on shares of Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th.

Perspective Therapeutics Stock Up 1.5%

Shares of CATX stock opened at $2.79 on Friday. Perspective Therapeutics has a 52-week low of $1.60 and a 52-week high of $5.39. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.66 and a quick ratio of 8.66. The company’s 50 day moving average is $2.48 and its 200 day moving average is $3.26.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its earnings results on Monday, November 10th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.02). The company had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.21 million. Perspective Therapeutics had a negative net margin of 9,841.86% and a negative return on equity of 40.03%. As a group, analysts predict that Perspective Therapeutics will post -0.88 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Perspective Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Taylor & Morgan Wealth Management LLC lifted its holdings in Perspective Therapeutics by 4.4% in the second quarter. Taylor & Morgan Wealth Management LLC now owns 94,000 shares of the company’s stock valued at $323,000 after acquiring an additional 4,000 shares during the period. Nicholson Wealth Management Group LLC increased its holdings in shares of Perspective Therapeutics by 0.3% during the 2nd quarter. Nicholson Wealth Management Group LLC now owns 1,614,283 shares of the company’s stock valued at $5,553,000 after purchasing an additional 5,000 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Perspective Therapeutics by 184.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock valued at $29,000 after purchasing an additional 5,475 shares during the period. MetLife Investment Management LLC boosted its holdings in Perspective Therapeutics by 40.9% during the first quarter. MetLife Investment Management LLC now owns 31,310 shares of the company’s stock worth $67,000 after buying an additional 9,082 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV grew its position in Perspective Therapeutics by 81.8% during the third quarter. Mercer Global Advisors Inc. ADV now owns 29,275 shares of the company’s stock valued at $100,000 after buying an additional 13,168 shares during the period. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.